Paratek Pharmaceuticals, Inc.
NASDAQ: PRTK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Evan Loh FACC, FAHA,
- Employees
- 268
- Headquarters
- Boston, United States
- IPO year
- 2009
- Market cap
- $127.8M
- Website
- https://paratekpharma.com
Loading PRTK…
Loading profile data…Frequently asked questions about PRTK
What does Paratek Pharmaceuticals, Inc. (PRTK) do?
Paratek Pharmaceuticals, Inc., a biopharmaceutical firm headquartered in Boston, Massachusetts, and founded in 1996, is actively engaged in the commercialization of its products. The company's core mission involves the creation and market introduction of crucial medical treatments for severe illnesses or major public health crises, intended for...
Where does PRTK trade?
Paratek Pharmaceuticals, Inc. (PRTK) trades on the NASDAQ Global Market.
What sector is PRTK in?
Paratek Pharmaceuticals, Inc. (PRTK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Paratek Pharmaceuticals, Inc.?
Evan Loh FACC, FAHA, is the chief executive officer of Paratek Pharmaceuticals, Inc. (PRTK).
Where is Paratek Pharmaceuticals, Inc. headquartered?
Paratek Pharmaceuticals, Inc. is headquartered in United States.
Does PRTK pay a dividend?
Yes — Paratek Pharmaceuticals, Inc. (PRTK) paid a trailing twelve-month dividend of USD 31.97 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did PRTK go public?
Paratek Pharmaceuticals, Inc. (PRTK) completed its initial public offering in 2009.